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Background. Although it is well known that obesity is a risk factor for gastrointestinal (GI) cancer, it is not well established if
obesity can cause earlier GI cancer onset. Methods. A cross-sectional study examining the linked 2004–2008 California Cancer
Registry Patient Discharge Database was performed to evaluate the association between obesity and onset age among four
gastrointestinal cancers, including esophageal, gastric, pancreatic, and colorectal cancers. Regression models were constructed to
adjust for other carcinogenic factors. Results. *e diagnosis of obesity (BMI> 30) was associated with a reduction in diagnosis age
across all four cancer types: 3.25± 0.53 years for gastric cancer, 4.56± 0.18 years for colorectal cancer, 4.73± 0.73 years for
esophageal cancer, and 5.35± 0.72 for pancreatic cancer. *e diagnosis of morbid obesity (BMI> 40) was associated with
a more pronounced reduction in the age of diagnosis: 5.48± 0.96 years for gastric cancer, 7.75± 0.30 years for colorectal cancer,
7.67± 1.26 years for esophageal cancer, and 8.19± 1.25 years for pancreatic cancer. Both morbid obesity and obesity remained
strongly associated with earlier cancer diagnosis for all four cancer types even after adjusting for other available cancer risk factors.
Conclusions. *e diagnosis of obesity, especially morbid obesity, was associated with a significantly earlier gastrointestinal cancer
onset in California. Further research with prospective cohort data may be required to establish the causal relationship between
obesity and cancer onset age.
1. Introduction
*e obesity epidemic has been growing at a steady rate
in the United States. Between 1960 and 2006, the number
of the overweight population has doubled, while the obese
population increased five-fold [1]. Within the obesity
epidemic, a subcohort of morbidly obese (BMI > 40) or
super obese (BMI > 50) patients has been growing at an
alarming rate. Between 1986 and 2000, the prevalence of
subjects with BMI over 30 roughly doubled, while the
prevalence of subjects with a BMI over 40 quadrupled, and
the prevalence of BMI over 50 quintupled [2]. Due to the
numerous chronic conditions associated with obesity,
about 26,000 excess deaths per year have been attributed to
obesity [3].
In addition to contributing to heart disease, stroke, and
diabetes, obesity is a major contributor to the nation’s cancer
toll. It has quickly overtaken tobacco as the leading pre-
ventable cause of cancer. Each year, as many as 84,000 cancer
diagnoses are attributed to obesity and being overweight and
obesity are implicated in 15% to 20% of total cancer-related
mortality [4]. Obesity has been found to be associated with
increased incidence of a variety of cancers, including
postmenopausal breast [5, 6], prostate [6], colorectal [7, 8],
esophageal adenocarcinomas [9], gastric [9], pancreas [10],
liver [11], and melanomas [12]. Cancer is predicted to
overtake heart disease as the leading cause of death in the
United States by 2030 [13]. Recently, the American Society of
Clinical Oncology published its first ever position statement
on obesity and cancer to increase education and awareness
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and help oncology providers to treat obesity in cancer pa-
tients [4].
Up to now, no studies have examined the link between
obesity and early cancer onset due to the lack of data with
sufficient longitudinal follow-up. Each cancer is usually as-
sociated with a specific age distribution. For example, gastric
cancers are commonly found in patients above 55 years old
[14], and colorectal and pancreatic cancers are usually di-
agnosed above 65 years old [15, 16], while esophageal cancer is
most commonly diagnosed between 45 and 70 years old [17].
Recently, researchers have observed a gradual increase in
incidence of early-onset colorectal cancers [18] concomitant
with the rise in obesity prevalence, raising the question
whether the observed earlier onset of cancers may be at-
tributable to obesity. Recognition of early cancer risk factors
are very important because patients with exposure to those
risk factors may need earlier and more frequent cancer
screening. As a cancer risk factor, we hypothesize that obesity
is associated with a younger age of onset for GI cancers and
this association correlates with the severity of obesity. To test
this hypothesis, we investigated the relationship between
obesity and four of the most common GI cancers including
esophageal, gastric, colon, and pancreatic cancer diagnosis age
using two population-based databases in the state of Cal-
ifornia between 2002 and 2008.
2. Material and Methods
A retrospective review of all incident cases of the four most
common GI cancers (esophageal, gastric, pancreatic, and
colorectal) among inpatients in California between 2002 and
2008 was performed. *e California Cancer Registry (CCR)
is a statewide cancer surveillance system that captures all
new cancer diagnoses by statute. Cancer onset age and
demographic information were obtained from CCR, which
was then linked to the California’s Patient Discharge Da-
tabase (PDD) in order to obtain information regarding
obesity status and coexistent carcinogenic risk factors. PDD
was assembled by the Office of Statewide Health Planning
and Development (OSHPD) and documents discharge in-
formation from all acute care hospitals licensed by the state
of California.*e linkage was performed by programmers at
the CCR using probabilistic data-matching techniques based
on Social Security Number (SSN), date of birth, and gender.
Deidentified data files were then provided to the research
team after the linkage.
Inclusion criteria were any patient diagnosed with
esophageal, gastric, pancreatic, and colorectal cancer be-
tween 2002 and 2008 and admitted to a hospital in the state
of California. Patients with one of the four cancers of interest
were identified from the CCR by International Classification
of Diseases for Oncology (ICD-O) code. Patients with car-
cinoma in situ (stage 0) had prior cancer history on the same
organ or had missing value with regard to age or diagnosis
age were excluded from the analyses.
2.1. Variables of Interest. *e primary exposure of interest
was obesity. Patients within the PDD database with obesity
were identified using the International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)
code 278.00, signifying obesity, defined as a body mass index
of greater than 30 kg/m2. Morbid obesity was identified
using ICD-9-CM code 278.01, signifying a body mass index
of greater than 40.
*e primary outcome of interest was the patient’s age at
the time of primary cancer diagnosis, which was derived
from deducting the birth date from diagnosis date within
CCR. Secondary outcome was early onset cancer, defined as
primary cancer diagnosis at an age of less than 50 years.
Additional covariates were those demographic factors
and medical comorbidities considered contributory to
carcinogenesis for each respective cancer in the literature.
Demographic factors included gender and race/ethnicity.
Medical comorbidities included tobacco dependence, alco-
holism, and inflammatory bowel disease. Information re-
garding insurance availability and access to cancer screening
for individual patients was not available in the database.
2.2. Statistical Analysis. Descriptive analyses were performed
for all available data and tabulated. Bivariate tables were
constructed to compare baseline demographics and comor-
bidities by obesity status for the full sample and within each
cancer type. *e age at cancer diagnosis was summarized as
mean and standard deviation, under the premise that the
underlying distribution assimilates normal distribution.
Categorical variables were examined for independence using
chi-squared tests and continuous variables were compared
using Student’s t-tests. In order to quantify the independent
association between obesity status and cancer onset age,
multivariate regression models were constructed to adjust for
confounding effects of available known carcinogenic factors.
All available cancer risk factors from the database were in-
cluded in the regression models with no differential variable
selection algorithm. As PDD data were clustered within
sampled hospitals, standard errors were estimated with
cluster-robust Huber-White estimators in our regression
models. Data analyses were executed using Stata MP Version
13.0 (StataCorp; College Station, TX). All reported p values
were two-sided with values less than 0.05 considered as
significant. Due to the deidentified retrospective nature of the
data, this study was considered from review by the UCLA
institutional review board.
3. Results
A total of 173,585 inpatients were diagnosed with one of the
four GI cancers between 2002 and 2008 in the state of
California. Among these, 3,611 patients were excluded due
to previous history of cancer on the same organ and 167
patients excluded due to unknown birth or diagnosis age,
leaving 169,807 patients for analysis. Of these, 158,758
(93.5%) were classified as nonobese, 8,312 (4.9%) as obese,
and 2,737 (1.6%) as morbidly obese. *e characteristics of
the study participants are reported in Table 1, stratified by
cancer type. Among the four GI cancers, colorectal cancer
patients had the highest rates of obesity (5.7%) and morbid
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obesity (1.9%), while esophageal cancer patients had the
lowest rates of obesity (3.1%) and morbid obesity (0.9%).
Due to the small sample sizes observed for morbidly obese
patients, we have elected to perform subsequent analyses
combining both genders as one group instead of performing
separate analyses for males and females. Onset age distri-
bution appeared to approximate normal distribution for all
four cancer types; therefore, t-tests were employed for
subsequent analyses.
A consistent association between onset age and obesity
was found for all four GI cancers. Obese patients (BMI> 30)
had a younger onset age than nonobese patients, and
morbidly obese patients (BMI> 40) had an even younger
onset age (see Table 2 & Figure 1). Patients who were di-
agnosed with GI cancer before the age of 50 were referred to
have early onset GI cancer. *e percentage of early onset
cancer was also highest among morbidly obese patients,
followed by obese and nonobese patients (Table 2). Obesity
and morbid obesity caused the most significant increase of
early cancer in esophageal cancer: a 56% increase in obese
patients and 166% increase in morbidly obese patients
(Table 2). *e strength of the association between obesity
and age of cancer diagnosis appeared to be correlated with
the severity of obesity.
*e American Joint Commission on Cancer stage
(AJCC, 6th edition), tumor histology, race, gender, and
other risks factors of cancer information were tabulated by
cancer type (Supplementary Tables 1 to 4). As expected,
obese and morbidly obese patients had a higher prevalence
of diabetes. However, there were no consistent correlations
between other cancer risk factors and diagnosis of obesity.
Despite an earlier cancer diagnosis, obese and morbidly
obese patients did not have lower AJCC cancer stage at the
time of diagnosis.
Regressionmodels were constructed for each cancer type
in order to examine the independent association between
obesity and onset age for the four GI cancers after adjusting
for other known etiologic factors. *e findings were com-
patible with the above-described results from the bivariate
analyses. When diagnosis age was examined as a continuous
variable using linear regression models, the diagnosis of
obesity was found to be independently associated with
a lower diagnosis age across all four cancer types, with
a reduction in age of diagnosis ranging from 3.25 years in
gastric cancer to 5.35 years in pancreatic cancer. *e di-
agnosis of morbid obesity was associated with a reduction in
the age of diagnosis ranging from 5.48 years in gastric cancer
to 8.19 years in pancreatic cancer (see Table 3). Other
common cancer risk factors such as alcoholism, male
gender, and smoking were all associated with earlier age of
diagnosis for all four GI cancers. Ulcerative colitis and
Crohn’s disease significantly decreased the onset age for
colon cancer: 8.45± 0.56 years and 7.45± 0.79 years earlier,
respectively.
4. Discussion
*e present study represents one of the first population
database-based studies demonstrating decreased mean GI
cancer onset age among obese patients in comparison with
nonobese patients. *e age at primary diagnosis of esoph-
ageal, gastric, pancreatic, and colorectal cancers were all
significantly lower among obese patients. *e strength of
this association was especially pronounced among patients
with morbid obesity.
In our linear regression analysis, almost all the common
known risk factors for GI cancers including obesity, alco-
holism, male gender, and smoking were found to be asso-
ciated with earlier cancer onset. *is is consistent with
previous studies that hypothesized a cancer age reduction
effect among carcinogenic factors, such as the decreased age
of diagnosis of lung cancer found among smokers [19–21].
Among the examined risk factors, obesity, especially morbid
obesity, had the most significant impact on early cancer
onset for all four cancers. Ulcerative colitis is one of the
strongest risk factors for colorectal cancer with the ap-
proximate cumulative incidence of 5 to 10 percent after 20
years and 12 to 20 percent after 30 years of disease [22]. In
our study, it had the most substantial impact on colon cancer
onset age among all known risk factors (8.45 years earlier
onset, and odds ratio of 3.08).*ese findings suggest that the
strength of the etiologic factor may be associated with the
age at cancer onset. Morbid obesity had a very similar age of
onset reduction as ulcerative colitis (7.75 years versus 8.45
years) for colon cancer, suggesting that morbid obesity is
a very strong risk factor for early onset of colon cancer. *e
subgroup of morbidly obese patients is among the fastest
growing obese population in the past decades and new data
from the CDC show that the prevalence of morbid obesity in
US was 7.7% in 2013-2014 [23]. *e results of our study
highlight the importance and urgency to conduct large
prospective studies to definitively establish the relationship
between morbid obesity and risk of early onset of cancer. If
our results are confirmed by prospective cohort studies,
morbidly obese patients may need to have much earlier and
more frequent GI cancer screening.
Several limitations exist in using a cross-sectional study
design to explore the association between cancer onset age
timing and obesity. First, significant undercoding of obesity
is likely in our administrative data source. Obesity was only
Table 1: Sample size by cancer type.
Cancer type Nonobese Obese Morbidly obese
Esophageal, no. (%) 8,952 (96.0%) 285 (3.1%) 92 (0.9%)
Pancreatic, no. (%) 26,834 (95.7%) 942 (3.4%) 277 (0.9%)
Colorectal, no. (%) 103,556 (92.4%) 6,325 (5.7%) 2,143 (1.9%)
Gastric, no. (%) 19,416 (95.2%) 760 (3.7%) 225 (1.1%)
Total, no. (%) 158,758 (93.5%) 8,312 (4.9%) 2,737 (1.6%)
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Table 2: Cancer diagnosis age by cancer type.
Cancer type Nonobese Obese Morbidly obese
Esophageal Diagnosis age, mean (SD) 68.9 (12.2) 63.7 (11.0
a) 61.8 (11.2)
Early onset, no. (%) 552 (6.2%) 28 (9.8%) 15 (16.5%)
Pancreatic Diagnosis age, mean (SD) 70.6 (12.8) 66.3 (11.7
a) 62.5 (11.8b)
Early onset, no. (%) 1,632 (6.1%) 79 (8.4%) 32 (11.6%)
Colorectal Diagnosis age, mean (SD) 69.2 (14.0) 65.3 (11.9
a) 62.6 (11.6b)
Early onset, no. (%) 9,722 (9.4%) 585 (9.2%) 266 (12.4%)
Gastric Diagnosis age, mean (SD) 68.5 (14.5) 65.2 (12.4
a) 63.0 (11.9b)
Early onset, no. (%) 2,197 (11.3%) 88 (11.6%) 36 (16.1%)
All four cancers Diagnosis age, mean (SD) 69.3 (13.8) 65.4 (11.9
a) 62.6 (11.6b)
Early onset, no. (%) 24,550 (8.3%) 1,322 (9.7%) 615 (13.9%)
aDenotes statistically significant difference between obese and nonobese diagnosis age (p< 0.05). bDenotes statistically significant difference betweenmorbidly
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Figure 1: Kernel density plot of diagnosis age distribution for four gastrointestinal cancers. Kernel density plots of cancer diagnosis age was
produced to estimate the relative age distribution of nonobese, obese, and morbidly obese patients who had esophageal (a), pancreatic (b),
colorectal (c), and gastric cancer (d). Due to the disparate sample size between BMI groups, kernel density, a nonparametric estimation of
the age distribution, was employed to create visual representations of the age distributions to allow comparison.
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designated as a disease by the AmericanMedical Association
(AMA) in 2013, therefore it is likely not regarded as a disease
entity worth coding before that time. In addition, a previous
study investigating the phenomenon of underreporting
obesity in medical records showed that physicians were
more likely to document obesity in patient records for those
with higher BMI scores or morbidly obese [24]. While CCR
has previously been used to conduct obesity epidemiological
studies in the literature [25, 26], the undercodingmay lead to
an exaggeration of the association between obesity and the
outcome of interest. Similarly, other clinical risk factors for
cancer, such as Helicobacter pylori infection, Barrett’s dis-
ease, etc. were not reliably present in the database, raising
risk for residual confounding with the regression models.
Another limitation is that the linked PDD-CCR database
captured new cancer cases diagnosed in California during
the study period only among inpatients, while it was known
that some cancer patients were never admitted to the
hospital due to advanced cancer stage where inpatient
treatment was deemed futile [27]. Another potential limi-
tation of the study is the survival bias, [28], stemming from
deaths due to competing causes; that is, subjects with obesity
were more likely to die from cardiac disease or stroke at
a younger age than control subjects before the development
of GI cancers [29]. Studies have shown that obesity,
smoking, alcoholism, and diabetes all were associated with
a significantly lower life expectancy and might be affected by
survival bias [30–32].
5. Conclusions
Our study demonstrated that obesity was associated with
a three- to five-year reduction and morbid obesity was as-
sociated with five to eight-year reduction in the age of di-
agnosis for four of the most common GI cancers. *is
finding may be relevant during future efforts in strategizing
the optimal age for GI cancer screening for the increasingly
prevalent morbidly obese population. Large prospective
studies with long-term follow-up are greatly needed to
definitively explore the association between cancer onset age
and obesity.
Conflicts of Interest
*e authors declare that they have no conflicts of interest.
Supplementary Materials
Supplementary Table 1: demographic and cancer in-
formation regarding esophageal cancer patients. Supple-
mentary Table 2: demographic and cancer information
regarding gastric cancer patients. Supplementary Table 3:
demographic and cancer information regarding pancreatic
cancer patients. Supplementary Table 4: demographic and
cancer information regarding colorectal cancer patients.
(Supplementary Materials)
References
[1] R. T. Hurt, C. Kulisek, L. A. Buchanan, and S. A. McClave,
“*e obesity epidemic: challenges, health initiatives, and
implications for gastroenterologists,” Gastroenterology &
Hepatology, vol. 6, no. 12, pp. 780–792, 2011.
[2] R. Sturm, “Increases in clinically severe obesity in the United
States, 1986–2000,” Archives of Internal Medicine, vol. 163,
no. 18, pp. 2146–2148, 2003.
[3] K. M. Flegal, B. I. Graubard, D. F. Williamson, andM. H. Gail,
“Cause-specific excess deaths associated with underweight,
overweight, and obesity,” JAMA, vol. 298, no. 17, pp. 2028–
2037, 2007.
[4] J. A. Ligibel, C. M. Alfano, K. S. Courneya et al., “American
Society of Clinical Oncology position statement on obesity
and cancer,” Journal of Clinical Oncology, vol. 32, no. 31,
pp. 3568–3574, 2014.
[5] R. L. Yung and J. A. Ligibel, “Obesity and breast cancer: risk,
outcomes, and future considerations,” Clinical Advances in
Hematology & Oncology, vol. 14, no. 10, pp. 790–797, 2016.
[6] E. H. Allott and S. D. Hursting, “Obesity and cancer:
mechanistic insights from transdisciplinary studies,”
Endocrine-Related Cancer, vol. 22, no. 6, pp. R365–R386,
2015.
[7] Y. Ma, Y. Yang, F. Wang et al., “Obesity and risk of colorectal
cancer: a systematic review of prospective studies,” PLoS One,
vol. 8, no. 1, Article ID e53916, 2013.
[8] C. M. Kitahara, S. I. Berndt, A. B. de Gonzalez et al., “Pro-
spective investigation of body mass index, colorectal ade-
noma, and colorectal cancer in the prostate, lung, colorectal,
and ovarian cancer screening trial,” Journal of Clinical On-
cology, vol. 31, no. 19, pp. 2450–2459, 2013.
[9] M. G. O’Doherty, N. D. Freedman, A. R. Hollenbeck,
A. Schatzkin, and C. C. Abnet, “A prospective cohort study of
obesity and risk of oesophageal and gastric adenocarcinoma
in the NIH-AARP Diet and Health Study,” Gut, vol. 61, no. 9,
pp. 1261–1268, 2012.
Table 3: Reduction in cancer diagnosis age associated with risk factors (covariates from multivariate linear regression, expressed in
covariate± standard error).
Esophageal cancer Pancreatic cancer Colorectal cancer Gastric cancer
Morbid obesityb −7.67± 1.26a −8.19± 1.25a −7.75± 0.30a −5.48± 0.96a
Obesityb −4.73± 0.73a −5.35± 0.72a −4.56± 0.18a −3.25± 0.53a
Smoking −1.66± 0.26a −1.68± 0.26a −0.33± 0.11a −0.71 ± 0.25a
Alcoholism −4.34± 0.45a −3.70± 0.47a −2.90± 0.26a −5.29± 0.54a
Male −3.24± 0.29a −3.32± 0.29a −2.52± 0.08a −0.94± 0.21a
Crohn’s — — −7.45± 0.79a —
Ulcerative colitis — — −8.45± 0.56a —
Residual 72.3± 0.26 72.1± 0.26 70.1± 0.06 69.4± 0.16
aDenotes statistical significance with p value< 0.05. bReduction in cancer onset age represents estimates using nonobese population as reference group.
Journal of Obesity 5
[10] Z. Cruz-Monserrate, D. L. Conwell, and S. G. Krishna, “*e
impact of obesity on gallstone disease, acute pancreatitis, and
pancreatic cancer,”Gastroenterology Clinics of North America,
vol. 45, no. 4, pp. 625–637, 2016.
[11] N. L. Nock, “Epidemiology,” in Obesity and Gastrointestinal
Cancers, S. D. Markowitz, Ed., pp. p1–p22, Springer, New
York, NY, USA, 2012.
[12] K. Karimi, T. H. Lindgren, C. A. Koch, and R. T. Brodell,
“Obesity as a risk factor for malignant melanoma and non-
melanoma skin cancer,” Reviews in Endocrine and Metabolic
Disorders, vol. 17, no. 3, pp. 389–403, 2016.
[13] American Society of Clinical Oncology, “*e state of cancer
care in America, 2014: a report by the American Society of
Clinical Oncology,” Journal of Oncology Practice, vol. 10, no. 2,
pp. 119–142, 2014.
[14] M. C. Camargo, M. C. Yepez, C. Ceron et al., “Age at ac-
quisition of Helicobacter pylori infection: comparison of two
areas with contrasting risk of gastric cancer,” Helicobacter,
vol. 9, no. 3, pp. 262–270, 2004.
[15] C. Jochem and M. Leitzmann, “Obesity and colorectal cancer,”
Recent Results in Cancer Research, vol. 208, pp. 17–41, 2016.
[16] W. S. Loc, J. P. Smith, G. Matters, M. Kester, and J. H. Adair,
“Novel strategies for managing pancreatic cancer,” World
Journal of Gastroenterology, vol. 20, no. 40, pp. 14717–14725,
2014.
[17] M. J. Domper Arnal, A. Ferrandez Arenas, and A. Lanas
Arbeloa, “Esophageal cancer: risk factors, screening and en-
doscopic treatment in western and eastern countries,” World
Journal of Gastroenterology, vol. 21, no. 26, pp. 7933–7943,
2015.
[18] L. C. Connell, M. J. Mota, M. I. Braghiroli, and P. M. Hoff,
“*e rising incidence of younger patients with colorectal
cancer: questions about screening, biology, and treatment,”
Current Treatment Options in Oncology, vol. 18, no. 4, p. 23,
2017.
[19] M. C. Pike and R. Doll, “Age at onset of lung cancer: sig-
nificance in relation to effect of smoking,”=eLancet, vol. 285,
no. 7387, pp. 665–668, 1965.
[20] W. Weiss, “Cigarette smoke as a carcinogen,” American
Review of Respiratory Disease, vol. 108, no. 2, pp. 364–366,
1973.
[21] A. M. Michalek and K. M. Cummings, “*e association be-
tween cigarette smoking and age at cancer diagnosis,”Human
Biology, vol. 59, no. 4, pp. 631–639, 1987.
[22] A. Ekbom, C. Helmick, M. Zack, and H. O. Adami, “Ul-
cerative colitis and colorectal cancer: A population-based
study,” New England Journal of Medicine, vol. 323, no. 18,
pp. 1228–1233, 1990.
[23] K. M. Flegal, D. Kruszon-Moran, M. D. Carroll, C. D. Fryar,
and C. L. Ogden, “Trends in obesity among adults in the
United States, 2005 to 2014,” JAMA, vol. 315, no. 21,
pp. 2284–2291, 2016.
[24] A. Mattar, D. Carlston, G. Sariol et al., “*e prevalence of
obesity documentation in Primary Care Electronic Medical
Records. Are we acknowledging the problem?,” Applied
Clinical Informatics, vol. 8, no. 1, pp. 67–79, 2017.
[25] J. Crisham, T. B. Newman, T. W. Cheng, G. Xing,
W. M. Gilbert, and Y. W. Wu, “Maternal diagnosis of obesity
and risk of cerebral palsy in the child,” Journal of Pediatrics,
vol. 163, no. 5, pp. 1307–1312, 2013.
[26] K. M. Flegal, M. D. Carroll, B. K. Kit, and C. L. Ogden,
“Prevalence of obesity and trends in the distribution of body
mass index among US adults, 1999-2010,” JAMA, vol. 307,
no. 5, pp. 491–497, 2012.
[27] M. Hidalgo, S. Cascinu, J. Kleeff et al., “Addressing the
challenges of pancreatic cancer: future directions for im-
proving outcomes,” Pancreatology, vol. 15, no. 1, pp. 8–18,
2015.
[28] J. A. Baron, “*e age-at-diagnosis fallacy,”Archives of Internal
Medicine, vol. 166, no. 15, p. 1670, 2006.
[29] C. M. Kitahara, A. J. Flint, A. Berrington de Gonzalez et al.,
“Association between class III obesity (BMI of 40–59 kg/m2)
and mortality: a pooled analysis of 20 prospective studies,”
PLoS Medicine, vol. 11, no. 7, Article ID e1001673, 2014.
[30] M. Stahre, J. Roeber, D. Kanny, R. D. Brewer, and X. Zhang,
“Contribution of excessive alcohol consumption to deaths and
years of potential life lost in the United States,” Preventing
Chronic Disease, vol. 11, p. E109, 2014.
[31] H. Jia, M. M. Zack, W. W. *ompson, and S. R. Dube,
“Quality-adjusted life expectancy (QALE) loss due to smoking
in the United States,” Quality of Life Research, vol. 22, no. 1,
pp. 27–35, 2013.
[32] O. H. Franco, E. W. Steyerberg, F. B. Hu, J. Mackenbach, and
W. Nusselder, “Associations of diabetes mellitus with total life
expectancy and life expectancy with and without cardiovas-
cular disease,” Archives of Internal Medicine, vol. 167, no. 11,
pp. 1145–1151, 2007.
6 Journal of Obesity
